The development of heart failure in patients with stable angina pectoris

George C. Sutton, Jan Erik Otterstad, Bridget Anne Kirwan, Z. Vokó, Sophie de Brouwer, Jacobus Lubsen, Philip A. Poole-Wilson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset. Methods and results: Of 7665 patients with stable angina in the ACTION trial, which compared long-acting nifedipine to placebo, 207 (2.7%) developed heart failure (HF) during a mean follow-up of 4.9 years. Those who developed HF were significantly (P <0.05) older, more often had diabetes, had a more extensive history of cardiovascular disease, lower ejection fractions, a higher serum creatinine and glucose, a lower haemoglobin, and were more often on blood pressure lowering drugs. A cardiac event or an intervention (n = 155), a significant non-cardiac infection (n = 19) or poor control of hypertension (n = 12) preceded the development of HF in 186/207 cases (90%). There was no obvious precipitating factor in the remaining 21 patients (10%). Myocardial infarction increased the risk of the development of new HF within one week more than 100-fold. Nifedipine reduced the incidence of HF by 29% (P = 0.015). Conclusions: The development of heart failure is uncommon in patients with stable angina, and even less so in the absence of an obvious precipitating factor.

Original languageEnglish
Pages (from-to)234-242
Number of pages9
JournalEuropean Journal of Heart Failure
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Stable Angina
Heart Failure
Precipitating Factors
Nifedipine
Creatinine
Hemoglobins
Cardiovascular Diseases
Myocardial Infarction
Placebos
Blood Pressure
Hypertension
Glucose
Incidence
Infection
Serum
Pharmaceutical Preparations

Keywords

  • Angina pectoris
  • Calcium channel blockers
  • Heart failure
  • Randomised controlled trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sutton, G. C., Erik Otterstad, J., Kirwan, B. A., Vokó, Z., de Brouwer, S., Lubsen, J., & Poole-Wilson, P. A. (2007). The development of heart failure in patients with stable angina pectoris. European Journal of Heart Failure, 9(3), 234-242. https://doi.org/10.1016/j.ejheart.2006.09.002

The development of heart failure in patients with stable angina pectoris. / Sutton, George C.; Erik Otterstad, Jan; Kirwan, Bridget Anne; Vokó, Z.; de Brouwer, Sophie; Lubsen, Jacobus; Poole-Wilson, Philip A.

In: European Journal of Heart Failure, Vol. 9, No. 3, 03.2007, p. 234-242.

Research output: Contribution to journalArticle

Sutton, GC, Erik Otterstad, J, Kirwan, BA, Vokó, Z, de Brouwer, S, Lubsen, J & Poole-Wilson, PA 2007, 'The development of heart failure in patients with stable angina pectoris', European Journal of Heart Failure, vol. 9, no. 3, pp. 234-242. https://doi.org/10.1016/j.ejheart.2006.09.002
Sutton, George C. ; Erik Otterstad, Jan ; Kirwan, Bridget Anne ; Vokó, Z. ; de Brouwer, Sophie ; Lubsen, Jacobus ; Poole-Wilson, Philip A. / The development of heart failure in patients with stable angina pectoris. In: European Journal of Heart Failure. 2007 ; Vol. 9, No. 3. pp. 234-242.
@article{da8848d294fa401d94a64229777dc20f,
title = "The development of heart failure in patients with stable angina pectoris",
abstract = "Background: To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset. Methods and results: Of 7665 patients with stable angina in the ACTION trial, which compared long-acting nifedipine to placebo, 207 (2.7{\%}) developed heart failure (HF) during a mean follow-up of 4.9 years. Those who developed HF were significantly (P <0.05) older, more often had diabetes, had a more extensive history of cardiovascular disease, lower ejection fractions, a higher serum creatinine and glucose, a lower haemoglobin, and were more often on blood pressure lowering drugs. A cardiac event or an intervention (n = 155), a significant non-cardiac infection (n = 19) or poor control of hypertension (n = 12) preceded the development of HF in 186/207 cases (90{\%}). There was no obvious precipitating factor in the remaining 21 patients (10{\%}). Myocardial infarction increased the risk of the development of new HF within one week more than 100-fold. Nifedipine reduced the incidence of HF by 29{\%} (P = 0.015). Conclusions: The development of heart failure is uncommon in patients with stable angina, and even less so in the absence of an obvious precipitating factor.",
keywords = "Angina pectoris, Calcium channel blockers, Heart failure, Randomised controlled trial",
author = "Sutton, {George C.} and {Erik Otterstad}, Jan and Kirwan, {Bridget Anne} and Z. Vok{\'o} and {de Brouwer}, Sophie and Jacobus Lubsen and Poole-Wilson, {Philip A.}",
year = "2007",
month = "3",
doi = "10.1016/j.ejheart.2006.09.002",
language = "English",
volume = "9",
pages = "234--242",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The development of heart failure in patients with stable angina pectoris

AU - Sutton, George C.

AU - Erik Otterstad, Jan

AU - Kirwan, Bridget Anne

AU - Vokó, Z.

AU - de Brouwer, Sophie

AU - Lubsen, Jacobus

AU - Poole-Wilson, Philip A.

PY - 2007/3

Y1 - 2007/3

N2 - Background: To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset. Methods and results: Of 7665 patients with stable angina in the ACTION trial, which compared long-acting nifedipine to placebo, 207 (2.7%) developed heart failure (HF) during a mean follow-up of 4.9 years. Those who developed HF were significantly (P <0.05) older, more often had diabetes, had a more extensive history of cardiovascular disease, lower ejection fractions, a higher serum creatinine and glucose, a lower haemoglobin, and were more often on blood pressure lowering drugs. A cardiac event or an intervention (n = 155), a significant non-cardiac infection (n = 19) or poor control of hypertension (n = 12) preceded the development of HF in 186/207 cases (90%). There was no obvious precipitating factor in the remaining 21 patients (10%). Myocardial infarction increased the risk of the development of new HF within one week more than 100-fold. Nifedipine reduced the incidence of HF by 29% (P = 0.015). Conclusions: The development of heart failure is uncommon in patients with stable angina, and even less so in the absence of an obvious precipitating factor.

AB - Background: To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset. Methods and results: Of 7665 patients with stable angina in the ACTION trial, which compared long-acting nifedipine to placebo, 207 (2.7%) developed heart failure (HF) during a mean follow-up of 4.9 years. Those who developed HF were significantly (P <0.05) older, more often had diabetes, had a more extensive history of cardiovascular disease, lower ejection fractions, a higher serum creatinine and glucose, a lower haemoglobin, and were more often on blood pressure lowering drugs. A cardiac event or an intervention (n = 155), a significant non-cardiac infection (n = 19) or poor control of hypertension (n = 12) preceded the development of HF in 186/207 cases (90%). There was no obvious precipitating factor in the remaining 21 patients (10%). Myocardial infarction increased the risk of the development of new HF within one week more than 100-fold. Nifedipine reduced the incidence of HF by 29% (P = 0.015). Conclusions: The development of heart failure is uncommon in patients with stable angina, and even less so in the absence of an obvious precipitating factor.

KW - Angina pectoris

KW - Calcium channel blockers

KW - Heart failure

KW - Randomised controlled trial

UR - http://www.scopus.com/inward/record.url?scp=33847369504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847369504&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2006.09.002

DO - 10.1016/j.ejheart.2006.09.002

M3 - Article

C2 - 17079189

AN - SCOPUS:33847369504

VL - 9

SP - 234

EP - 242

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -